Involvement of arginine vasopressin and V1b receptor in heroin withdrawal and heroin seeking precipitated by stress and by heroin

Neuropsychopharmacology

Volumn 33, Issue 2, 2008, Pages 226-236

  Zhou, Yan ^a   Leri, Francesco ^b   Cummins, Erin ^b   Hoeschele, Marisa ^b   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF GUELPH   (Canada)

Author keywords

Amygdala; Arginine vasopressin; Heroin withdrawal; Reinstatement; Stress; V1b receptor

Indexed keywords

1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; ARGIPRESSIN; DIAMORPHINE; MESSENGER RNA; VASOPRESSIN V1B RECEPTOR;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; FOOTSHOCK; HEROIN DEPENDENCE; HORMONE RESPONSE; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STRESS;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ARGININE VASOPRESSIN; CORTICOSTERONE; EXPLORATORY BEHAVIOR; HEROIN; HEROIN DEPENDENCE; MALE; RATS; RATS, INBRED F344; RECEPTORS, VASOPRESSIN; RNA, MESSENGER; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 36949023768     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301419     Document Type: Article

References (60)

1. Aguilera G, Rabadan-Diehl C (2000). Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul Pept 96: 23-29.
2. Bossert JM, Ghitza UE, Lu L, Epstein DH, Shaham Y (2005). Neurobiology of relapse to heroin and cocaine seeking: an update and clinical implications. Eur J Pharmacol 526: 36-50.
3. Branch A, Unterwald E, Lee S, Kreek MJ (1992). Quantitation of preproenkephalin mRNA levels in brain regions from male Fischer rats following chronic cocaine treatment using a recently developed solution hybridization assay. Mol Brain Res 14: 231-238.
4. Buckingham JC, Cooper TA (1984). Differences in hypothalamopituitary- adrenocortical activity in the rat after acute and prolonged treatment with morphine. Neuroendocrinology 38: 411-417.
5. De Vry J, Donselaar I, van Ree JM (1988). Effects of desglycinamide9, (Arg8) vasopressin and vasopressin antiserum on the acquisition of intravenous cocaine self-administration in the rat. Life Sci 42: 2709-2715.
6. De Wied D, Diamant M, Fodor M (1993). Central nervous system effects of the neurohypophyseal hormones and related peptides. Front Neuroendocrinol 14: 251-302.
7. De Wit H, Stewart J (1983). Drug reinstatement of heroin-reinforced responding in the rat. Psychopharmacology 79: 29-31.
8. Ebner K, Wotjak C, Landgraf R, Engelmann M (2002). Forced swimming triggers vasopressin release within the amygdala to modulate stress-coping strategies in rats. Eur J Neurosci 15: 384-388.
9. Erb S, Hitchcott PK, Rajabi H, Mueller D, Shaham Y, Stewart J (2000). Alpha-2 adrenergic receptor agonists block stress-induced reinstatement of cocaine seeking. Neuropsychopharmacology 23: 138-150.
10. Erb S, Shaham Y, Stewart J (1996). Stress reinstates cocaine-seeking behavior after prolonged extinction and a drug-free period. Psychopharmacology 128: 408-412.
11. Erb S, Shaham Y, Stewart J (1998). The role of corticotropin-releasing factor and corticosterone in stress- and cocaine-induced relapse to cocaine seeking in rats. J Neurosci 18: 5529-5536.
12. Erb S, Stewart J (1999). A role for the bed nucleus of the stria terminalis, but not the amygdala, in the effects of corticotropin-releasing factor on stress-induced reinstatement of cocaine seeking. J Neurosci 19: RC35.
13. Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B et al. (2002). Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 99: 6370-6375.
14. Griebel G, Stemmelin J, Gal CS, Soubrie P (2005). Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. Curr Pharm Des 11: 1549-1559.
15. Guillon G, Derick S, Pena A, Cheng LL, Stoev S, Seyer R et al. (2004). The discovery of novel vasopressin V1b receptor ligands for pharmacological, functional and structural investigations. J Neuroendocrinol 16: 356-361.
16. Hatfield T, Spanis C, McGaugh JL (1999). Response of amygdalar norepinephrine to footshock and GABAergic drugs using in vivo microdialysis and HPLC. Brain Res 835: 340-345.
17. Houshyar H, Gomez F, Manalo S, Bhargava A, Dallman MF (2003). Intermittent morphine administration induces dependence and is a chronic stressor in rats. Neuropsychopharmacology 28: 1960-1971.
18. Huber D, Veinante P, Stoop R (2005). Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 308: 245-248.
19. Ignar DM, Kuhn CM (1990). Effects of specific mu and kappa opiate tolerance and abstinence on hypothalamo-pituitary-adrenal axis secretion in the rat. J Pharmacol Exp Ther 225: 1287-1295.
20. Koob GF, Le Moal M (1997). Drug abuse: hedonic homeostatic dysregulation. Science 278: 52-58.
21. Kreek MJ, Borg L, Zhou Y, Schluger J (2002). Relationships between endocrine functions and substance abuse syndromes: heroin and related short-acting opiates in addiction contrasted with methadone and other long-acting opioid agonists used in pharmacotherapy of addiction. In: Pfaff DW (eds). Hormones, Brain and Behavior. Academic Press: San Diego. pp 781-830.
22. Kreek MJ, Koob GF (1998). Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend 51: 23-47.
23. Kruzich PJ, Chen AC, Unterwald EM, Kreek MJ (2003). Subject-regulated dosing alters morphine self-administration behavior and morphine-stimulated [35S]GTPgammaS binding. Synapse 47: 243-249.
24. Landgraf R, Neumann ID (2004). Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front Neuroendocrinol 25: 150-176.
25. Leri F, Flores J, Rodaros D, Stewart J (2002). Blockade of stress-induced but not cocaine-induced reinstatement by infusion of noradrenergic antagonists into the bed nucleus of the stria terminalis or the central nucleus of the amygdala. J Neurosci 22: 5713-5718.
26. Leri F, Stewart J (2001). Drug-induced reinstatement to heroin and cocaine seeking: a rodent model of relapse in poly-drug use. Exp Clin Psychopharmacol 9: 297-306.
27. Leri F, Tremblay A, Sorge RE, Stewart J (2004). Methadone maintenance reduces heroin- and cocaine-induced relapse without affecting stress-induced relapse in a rodent model of poly-drug use. Neuropsychopharmacology 29: 1312-1320.
28. Leri F, Zhou Y, Goddard B, Cummins E, Kreek MJ (2006). Effects of high dose methadone maintenance on cocaine place conditioning, cocaine self-administration, and mu-opioid receptor mRNA expression in the rat brain. Neuropsychopharmacology 31: 1462-1474.
29. Markou A, Kosten TR, Koob GF (1998). Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 18: 135-174.
30. McFarland K, Davidge SB, Lapish CC, Kalivas PW (2004). Limbic and motor circuitry underlying footshock-induced reinstatement of cocaine-seeking behavior. J Neurosci 24: 1551-1560.
31. Milanes MV, Laorden ML, Angel E, Tankosic P, Burlet A (2002). Effect of naloxone-precipitated morphine withdrawal on CRH and vasopressin mRNA expression in the rat hypothalamic paraventricular nucleus. Neurosci Lett 15: 586-591.
32. Nikolarakis KE, Almeida OFX, Herz A (1987). Feedback inhibition of opioid peptide release in the hypothalamus of the rat. Neuroscience 23: 143-148.
33. Overstreet DH, Griebel G (2005). Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat. Pharmacol Biochem Behav 82: 223-227.
34. Paxinos G, Watson C (1986). The Rat Brain in Stereotaxic Coordinates. 2nd edn. Academic Press: New York, NY.
35. Post RM, Contel NR, Gold P (1982). Impaired behavioral sensitization to cocaine in vasopressin deficient rats. Life Sci 31: 2745-2750.
36. Quirarte GL, Galvez R, Roozendaal B, McGaugh JL (1998). Norepinephrine release in the amygdala in response to footshock and opioid peptidergic drugs. Brain Res 808: 134-140.
37. Raber J, Bloom FE (1996). Arginine vasopressin release by acetylcholine or norepinephrine: region-specific and cytokine-specific regulation. Neuroscience 71: 747-759.
38. Serradeil-Le GC, Derick S, Brossard G, Manning M, Simiand J, Gaillard R et al. (2003). Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals. Stress 6: 199-206.
39. Shaham Y, Erb S, Stewart J (2000a). Stress-induced relapse to heroin and cocaine seeking in rats: a review. Brain Res Rev 33: 13-33.
40. Shaham Y, Funk D, Erb S, Brown TJ, Walker CD, Stewart J (1997). Corticotropin-releasing factor, but not corticosterone, is involved in stress-induced relapse to heroin seeking in rats. J Neurosci 17: 2605-2614.
41. Shaham Y, Highfield D, Delfs J, Leung S, Stewart J (2000b). Clonidine blocks stress-induced reinstatement of heroin seeking in rats: an effect independent of locus coeruleus noradrenergic neurons. Eur J Neurosci 12: 292-302.
42. Shaham Y, Rajabi H, Stewart J (1996). Relapse to heroin-seeking in rats under opioid maintenance: the effects of stress, heroin, priming and withdrawal. J Neurosci 16: 1957-1963.
43. Shaham Y, Shalev U, Lu L, de Wit H, Stewart J (2003). The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 168: 3-20.
44. Shiomi H, Watson SJ, Kelsey JE, Akil H (1986). Pretranslational and posttranslational mechanisms for regulation beta-endorphin-adrenocorticotropin of the anterior pituitary lobe. Endocrinology 119: 1793-1799.
45. Sim-Selley LJ, Selley DE, Vogt LJ, Childers SR, Martin TJ (2000). Chronic heroin self-administration desensitizes mu opioid receptor-activated G-proteins in specific regions of rat brain. J Neurosci 20: 4555-4562.
46. Sinha R (2001). How does stress increase risk of drug abuse and relapse? Psychopharmacology 158: 343-359.
47. Sinha R, Catapano D, O'Malley S (1999). Stress-induced craving and stress response in cocaine dependent individuals. Psychopharmacology 142: 343-351.
48. Sinha R, Garcia M, Paliwal P, Kreek MJ, Rounsaville BJ (2006). Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. Arch Gen Psychiatry 63: 324-331.
49. Stemmelin J, Lukovic L, Salome N, Griebel G (2005). Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415. Neuropsychopharmacology 30: 35-42.
50. Stewart J (2000). Pathways to relapse: the neurobiology of drug-and stress-induced relapse to drug-taking. J Psychiatry Neurosci 25: 125-136.
51. Stewart J (2003). Stress and relapse to drug seeking: studies in laboratory animals shed light on mechanisms and sources of long-term vulnerability. Am J Addict 12: 1-17.
52. van Ree JM, Burbach-Bloemarts EM, Wallace M (1988). Vasopressin neuropeptides and acquisition of heroin and cocaine self-administration in rats. Life Sci 42: 1091-1099.
53. van Ree JM, De Wied D (1977). Modulation of heroin self-administration by neurohypophyseal principles. Eur J Pharmacol 43: 199-202.
54. van Ree JM, Gerrits MAFM, Vanderschuren LJMJ (1999). Opioids, reward and addiction: an encounter of biology, psychology, and medicine. Pharmacol Rev 51: 341-396.
55. Wigger A, Sánchez MM, Mathys KC, Ebner K, Frank E, Liu D et al. (2004). Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin. Neuropsychopharmacology 29: 1-14.
56. Yao L, McFarland K, Fan P, Jiang Z, Inoue Y, Diamond I (2005). Activator of G protein signaling 3 regulates opiate activation of protein kinase A signaling and relapse of heroin-seeking behavior. Proc Natl Acad Sci USA 102: 8746-8751.
57. Zhou Y, Bendor JT, Hofmann L, Randesi M, Ho A, Kreek MJ (2006). Mu opioid receptor and orexin/hypocretin mRNA levels in the lateral hypothalamus and striatum are enhanced by morphine withdrawal. J Endocrinol 191: 137-145.
58. Zhou Y, Bendor JT, Yuferov V, Schlussman SD, Ho A, Kreek MJ (2005). Amygdalar vasopressin mRNA increases in acute cocaine withdrawal: evidence for opioid receptor modulation. Neuroscience 134: 1391-1397.
59. Zhou Y, Spangler R, LaForge KS, Maggos CE, Ho A, Kreek MJ (1996). Corticotropin-releasing factor and type 1 corticotropin-releasing factor receptor messenger RNAs in rat brain and pituitary during 'binge' pattern cocaine administration and chronic withdrawal. J Pharmacol Exp Ther 279: 351-358.
60. Zhou Y, Spangler R, Schlussman SD, Ho A, Kreek MJ (2003). Alterations in hypothalamic-pituitary-adrenal axis activity and in levels of proopiomelanocortin and corticotrophin-releasing hormone receptor 1 mRNAs in the pituitary and hypothalamus of the rat during chronic 'binge' cocaine and withdrawal. Brain Res 964: 187-199.